When pancreatic cancer comes back after the first round of treatment, the conversation in the oncologist's office has been painfully short for a long time.
More chemotherapy is usually the only offer. It can help, but the benefit is often measured in a few short months, and the side effects can be rough.
That is why the news out of Europe this week matters.
On November 16, 2026, the European Commission approved Rasonque (daraxonrasib), a once-a-day pill for adults with metastatic pancreatic cancer whose disease has already been treated with at least one prior therapy. It is the first broad RAS-targeted medicine ever approved for this disease.
The approval rests on a large Phase 3 trial, published in The New England Journal of Medicine, in which the pill nearly doubled median survival compared with chemotherapy: 13.2 months versus 6.7 months.
The United States approved the same drug in August 2026. Europe's decision now brings it to patients across the European Union — and it lands in the middle of Pancreatic Cancer Awareness Month.
If you or someone you love is facing pancreatic cancer that has spread, this post explains what this drug is, what the trial actually showed, what the side effects look like, and what questions are worth asking the care team.
What Is Metastatic Pancreatic Cancer?
The pancreas is a small organ tucked behind the stomach. It makes digestive juices and hormones, including insulin.
Pancreatic adenocarcinoma — often shortened to PDAC — is the most common type of pancreatic cancer. It starts in the cells that line the ducts of the pancreas.
"Metastatic" means the cancer has spread beyond the pancreas to other parts of the body, such as the liver or lungs.
A few facts explain why this disease is so hard to treat:
- It is usually found late. Early pancreatic cancer rarely causes clear symptoms, so most people are diagnosed after it has already spread.
- It grows in a dense, scar-like tissue that can shield the tumor.
- It tends to resist many standard drugs.
- It is driven, in more than 9 out of 10 cases, by mutations in a family of genes called RAS.
That last point is the key to this week's news. For decades, those RAS mutations were considered impossible to drug. Rasonque is the first approved medicine designed to go after them broadly.
"RAS Is Undruggable": The Myth This Drug Broke
To understand why oncologists are excited, it helps to know the backstory.
RAS proteins act like growth switches inside cells. In a healthy cell, the switch turns on to signal "grow," then turns back off.
In most pancreatic cancers, the switch is broken. It gets stuck in the "on" position, telling the cell to grow and divide without stopping.
Scientists discovered the RAS problem roughly 40 years ago. Then they spent those 40 years failing to block it.
The RAS protein was often described as smooth, like a billiard ball, with no pockets for a drug to grab onto. "Undruggable" became its nickname in cancer research.
For about 40 years, the main growth switch in pancreatic cancer was considered impossible to block. Rasonque is the first approved drug that blocks it across many mutation types.
Rasonque does not just block one rare version of the switch. It was designed to block many RAS variants at once. That is what "broad RAS-targeted" means, and it is why this approval is a first.
How Rasonque Works
It jams the switch while it is switched on
Most earlier attempts tried to catch RAS in its "off" state. Rasonque goes after RAS in its active, "on" state — what scientists call RAS(ON).
Think of a light switch that is stuck on. Instead of waiting for it to turn off, this drug walks up and jams it in place so the "grow" signal cannot get through.
It uses a helper protein as a handle
The drug grabs onto a helper protein in the cell called cyclophilin A. Together, the drug and the helper protein latch onto RAS and shut down its signaling.
That three-part latch is why the drug can work against many different RAS mutations, including the most common ones in pancreatic cancer, such as G12D, G12V, and G12R.
It is a pill taken once a day
Rasonque is taken by mouth, 300 mg once a day, at about the same time each day, with or without food. The tablets are swallowed whole.
Treatment continues as long as it is helping and the side effects are manageable. There are no infusion appointments and no IV lines for this therapy itself.
Why This Matters for Daily Life
A survival number is only part of the story. How a treatment fits into a person's life matters too, especially with a disease this serious.
In the trial behind this approval, patients on Rasonque reported benefits that go beyond scans:
- Pain took much longer to get worse — a median of 9.0 months before pain deteriorated, versus 3.7 months on chemotherapy.
- Overall quality of life held up longer — 5.6 months before global health status deteriorated, versus 2.4 months on chemotherapy.
- Treatment happens at home. A daily pill avoids the travel, waiting rooms, and infusion chairs that come with IV chemotherapy.
One caution about comparing numbers: a single score or a single month count never tells the whole story of how a person feels. But when survival, pain, and quality of life all point in the same direction, that pattern is worth paying attention to.
What Did the RASolute 302 Trial Find?
The approval is based on the RASolute 302 trial, a Phase 3 study published in The New England Journal of Medicine in May 2026.
The basics:
- 500 patients at 59 sites in six countries
- All had metastatic pancreatic adenocarcinoma that had already been treated
- Patients were randomly assigned to Rasonque or to standard chemotherapy chosen by their doctor
- The main analysis group was patients whose tumors carried RAS G12 mutations — about 92% of everyone enrolled
- Results so far come from the trial's first planned analysis, with a median follow-up of 8.5 months
Finding #1: People lived about twice as long
Median overall survival was 13.2 months with Rasonque versus 6.7 months with chemotherapy.
That is a 60% lower risk of death at any given time during the study period (hazard ratio 0.40).
In plain terms: in a disease where second-line chemotherapy typically buys months, the pill roughly doubled the typical survival time.
Finding #2: The cancer stayed quiet about twice as long
Median progression-free survival — the time until the cancer grew or the patient died — was 7.2 months versus 3.6 months.
For a patient, that can mean more months of stability: more ordinary days before the next hard conversation about changing treatment.
Finding #3: Far more tumors shrank
About 1 in 3 patients on Rasonque had their tumor shrink measurably (33.2% in the main RAS G12 group), compared with about 1 in 9 on chemotherapy (11.8%).
Tumor shrinkage is not the same as a cure. But in pancreatic cancer, where response rates to second-line chemotherapy have long been low, tripling the response rate is a meaningful step.
Finding #4: Pain and quality of life lasted longer
As noted above, pain worsening was delayed from 3.7 to 9.0 months, and decline in overall health status was delayed from 2.4 to 5.6 months.
Patients on the pill did not just live longer on average. Their pain and overall quality of life also held up for roughly twice as long as on chemotherapy.
Finding #5: Serious side effects were no more common than with chemo
Grade 3 (severe) side effects occurred in 61.8% of patients on Rasonque and 69.6% of patients on chemotherapy.
The side effects were different in kind, not clearly worse overall. The next section covers what they look like day to day, because managing them well is part of making this treatment work.
Side Effects: What to Expect and How Supportive Care Helps
Every effective cancer drug has a cost. With Rasonque, the most common side effects involve the skin, the mouth, and the gut.
In the trial, the most frequent side effects on Rasonque were:
- Rash — 85% of patients (severe in 14%)
- Diarrhea — 58% (severe in 5%)
- Mouth sores (stomatitis) — 53% (severe in 12%)
- Nausea — 46%
- Vomiting — 37%
- Also reported: tiredness, stomach pain, swelling, reduced appetite, and bleeding
Skin care starts on day one
The rash with this drug is common enough that the official prescribing information recommends prevention from the very start of treatment:
- A prescription steroid cream applied to the face and chest
- Moisturizing (emollient) creams
- Limiting sun exposure and using broad-spectrum sunscreen, SPF 30 or higher
- Sometimes a preventive antibiotic, such as doxycycline, if the care team recommends it
Do not wait for a rash to become painful before calling the team. Early treatment of skin reactions is much easier than late treatment.
Diarrhea, hydration, and electrolytes
Diarrhea was reported by more than half of patients. Most cases were mild or moderate, but diarrhea deserves respect during cancer treatment.
Each episode drains water and electrolytes — sodium, potassium, and magnesium — from the body. Losing them faster than you replace them can lead to dehydration, weakness, dizziness, and, in serious cases, kidney or heart rhythm problems.
Practical steps that help many patients:
- Sip fluids steadily through the day rather than drinking large amounts at once.
- Include oral rehydration drinks or electrolyte-containing fluids, especially on high-output days.
- Eat small, bland, low-fiber meals while diarrhea is active.
- Track how many episodes you have each day. A clear count helps the care team decide when to adjust treatment.
- Ask about anti-diarrheal medicine before you need it, so you know exactly what to take and when.
Call the care team promptly for diarrhea that does not settle, dizziness when standing, very low urine output, or a fever.
Mouth sores and appetite
Mouth sores affected about half of patients. Sore mouths make eating and drinking hurt, which can quietly spiral into poor nutrition and weight loss.
Soft, cool foods, gentle oral hygiene, and avoiding spicy or acidic foods can help. Tell the team early — there are rinses and medicines that can ease mouth sores, and catching them early protects your ability to eat.
Reduced appetite was also reported. Small, frequent, protein-rich meals and snacks usually work better than three large meals when appetite is low.
The pattern with this drug is manageable but real: skin, mouth, and gut. The patients who do best are usually the ones who report these problems early instead of pushing through them.
What Should Patients and Caregivers Watch For?
Contact the oncology team if you notice any of the following:
- A rash that spreads, blisters, peels, or becomes painful
- Diarrhea that keeps increasing, or any dizziness or light-headedness
- Mouth sores that make it hard to eat, drink, or swallow
- Vomiting that prevents you from keeping fluids down
- New or worsening cough or shortness of breath
- Severe stomach pain
- Unusual bruising or bleeding
- Fever of 100.4°F (38°C) or higher
- Rapid weight loss or a clear drop in appetite over a week or two
- Confusion, extreme tiredness, or very low urine output
When in doubt, call. Oncology teams would always rather hear about a side effect early, while it is still easy to manage.
Questions to Ask the Oncology Team
- Is Rasonque (daraxonrasib) an option for my cancer, given the treatment I have already had?
- Do I need a RAS mutation test result to receive it — and has my tumor been tested?
- I understand Europe approved it for patients regardless of whether a RAS mutation was found. Does that apply in my case?
- When will it actually be available at my hospital or in my country, and what does the rollout look like?
- What results should I realistically expect — and how will we know if it is working?
- What skin care should I start on day one to prevent the rash?
- What is our plan if I get diarrhea? Which fluids and medicines should I have at home?
- What should I do if mouth sores make eating painful?
- How often will I have scans, blood tests, and check-ins on this treatment?
- If this drug stops working, what are the next options — including clinical trials?
What Is Being Tested Next?
Approvals are rarely the end of a drug's story. They are usually the start of a bigger set of questions.
For daraxonrasib, studies are already asking whether it can help earlier and in combination:
- First-line treatment. The RASolute 303 trial is testing daraxonrasib-based treatment in people who have not yet had therapy for metastatic disease, where the need is greatest.
- After surgery. The RASolute 304 trial is testing it in patients whose cancer was removed surgically, aiming to lower the chance of the cancer coming back.
- Combinations. Other studies (RASolute 305 and 309) pair daraxonrasib with chemotherapy or with a second, mutation-specific RAS drug called zoldonrasib.
- Next-generation drugs. A related drug, elironrasib, targets a different RAS mutation (G12C) and is in earlier testing.
There is also an honest scientific caveat. Researchers studying patients whose cancer grew again on daraxonrasib found new resistance changes in about 45% of the tumor samples they examined. In other words, the cancer adapts — which is exactly why the combination and next-generation studies above matter.
None of these trials has reported results yet. If you are interested in joining one, the question list in the next sections can help you start that conversation with your team.
Why This Approval Matters
Pancreatic cancer has been one of oncology's most stubborn problems. Progress has come slowly, and many promising ideas have failed.
This approval matters for three reasons.
First, it is a genuinely new approach. Rasonque is not another variation of chemotherapy. It is the first approved drug that targets RAS — the driver in more than 90% of pancreatic cancers — across many mutation types.
Second, the benefit is large by this disease's standards. Doubling median survival, tripling the response rate, and delaying pain and quality-of-life decline, all in the same trial, is unusual in previously treated pancreatic cancer.
Third, it is a platform, not just a pill. Trials are already testing daraxonrasib earlier in treatment, after surgery, and in combinations, alongside next-generation RAS drugs from the same research program. Whether those studies succeed is unknown, but the direction of research has clearly changed.
It is also worth saying plainly what this approval is not:
- It is not a cure. The cancer eventually found ways around the drug in many patients, and researchers have already documented resistance.
- It is not for everyone. The approval covers adults with metastatic disease who have already received at least one prior systemic therapy. In Europe, availability will still roll out country by country.
- The survival results come from an early analysis of the trial, with a median follow-up of 8.5 months. Longer follow-up will sharpen the picture.
The Bottom Line
- On November 16, 2026, Europe approved Rasonque (daraxonrasib), a once-daily pill, for metastatic pancreatic cancer after prior treatment — with or without a found RAS mutation.
- In the Phase 3 RASolute 302 trial, median survival was 13.2 months versus 6.7 months with chemotherapy, and the risk of death was 60% lower.
- Tumors shrank in about 1 in 3 patients, versus about 1 in 9 on chemotherapy.
- Pain worsening and quality-of-life decline were delayed by roughly twofold.
- The most common side effects are rash, diarrhea, and mouth sores. Prevention and early reporting make a real difference.
- The drug was already approved in the United States in August 2026. European availability will phase in by country.
This does not mean every patient with pancreatic cancer should take this drug, or that it will work for every person who does. It does mean that, for the first time, there is an approved pill that goes directly after the most common driver of this disease — and that is a real change worth knowing about.
Frequently Asked Questions
What is Rasonque (daraxonrasib)?
Rasonque is a once-daily pill that blocks RAS, a growth-switch protein that is mutated in more than 90% of pancreatic cancers. It was developed by Revolution Medicines and is the first broad RAS-targeted medicine approved for pancreatic cancer.
Who is Rasonque approved for in Europe?
Adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy. The European approval applies whether or not a RAS mutation was identified in the tumor.
When was Rasonque approved?
The US Food and Drug Administration approved it on August 26, 2026. The European Commission approved it on November 16, 2026, for all European Union member states and the European Economic Area. Availability within each country depends on local pricing and reimbursement decisions.
How well did Rasonque work in its trial?
In the Phase 3 RASolute 302 trial of 500 patients, median survival was 13.2 months on Rasonque versus 6.7 months on chemotherapy. About 33% of patients in the main analysis group had their tumors shrink, versus about 12% on chemotherapy.
Do I need a specific mutation for Rasonque to work?
The drug was designed to block many RAS variants at once, and the European approval does not require a RAS mutation to be found. Most patients in the trial (about 92%) had RAS G12 mutations, and the benefit was also seen in the overall study population. Your oncology team can explain what testing shows in your case.
How is Rasonque taken?
By mouth, 300 mg once a day, at about the same time each day, with or without food. Tablets are swallowed whole. Treatment continues until the cancer progresses or side effects become unacceptable.
What are the most common side effects of Rasonque?
Rash (85% of patients in the trial), diarrhea (58%), mouth sores (53%), nausea (46%), and vomiting (37%). Tiredness, stomach pain, swelling, reduced appetite, and bleeding were also reported. Severe side effects overall were no more common than with chemotherapy.
Can the rash be prevented?
The prescribing information recommends starting preventive skin care with the drug: a steroid cream for the face and chest, moisturizers, sun protection with SPF 30 or higher, and sometimes a preventive antibiotic. Report any rash early — it is easier to treat at the start.
Is Rasonque a cure for pancreatic cancer?
No. It is an important advance that extended survival and delayed symptoms in a large trial, but the cancer can become resistant to it. Research into combinations and next-generation RAS drugs is ongoing.
What should I ask my oncologist about Rasonque?
Whether it fits your treatment history, whether your tumor has been tested for RAS mutations, when it will be available where you live, and what the plan is for preventing and managing rash, diarrhea, and mouth sores. The question list earlier in this post is a good starting point.
Sources
- Revolution Medicines — "European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer" (November 16, 2026).
- O'Reilly EM, Wainberg ZA, Hendifar AE, et al. "Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer." New England Journal of Medicine, published May 31, 2026.
- US Food and Drug Administration — "FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma" (August 26, 2026).
- RASONQUE (daraxonrasib) US Prescribing Information. DailyMed, revised August 2026.
- OncLive — "Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer" (November 16, 2026).
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.